Viral vector manufacturing companies play a pivotal role in the field of biotechnology and gene therapy, providing crucial tools for delivering therapeutic genes into target cells. These vectors are essential components in the development of advanced treatments for various genetic and acquired diseases.
Latest Viral Vector Manufacturing Companies Updates:
Lonza: Expanded its viral vector manufacturing capacity with a new facility in Switzerland, offering commercial-scale production for diverse gene therapy applications.
Sartorius: Acquired Cell & Gene Therapy Platform from Sartorius Stedim Biotech, gaining expertise and technologies for large-scale viral vector production using single-use bioreactors.
Catalent: Introduced its Opti™Viral platform, a modular and scalable solution for optimizing viral vector design and manufacturing processes, aiming to accelerate development and reduce costs.
Boehringer Ingelheim: Partnered with Viral Vector Producer to manufacture its innovative gene therapy candidate for treating beta-thalassemia, demonstrating commitment to advancing the field.
Charles River: Partnered with Rznomics, a South Korean biopharma, to develop and manufacture viral vectors for a gene therapy targeting liver cancer, highlighting collaborative efforts in Asia.
The Alliance for Regenerative Medicine (ARM): Collaborated with industry leaders and regulatory bodies to advocate for streamlined regulations and promote responsible development of viral vector-based therapies.
List of Viral Vector Manufacturing  Key companies in the market:
Catalent Inc.
Avid Bioservices Inc.
AGC Biologics
Thermofisher Scientific Inc.
Cognate Bioservices
FinVector
Merck KgaA
Waisman Biomanufacturing
GenScript Biotech Corporation
Viral Vector Manufacturing Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)